From: Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan
 | Overall (n = 2663) | Anticoagulant group (n = 1247) | Control group (n = 1416) | P value |
---|---|---|---|---|
Patient characteristics | ||||
 Age in years | 73 (63–81) | 72 (62–80) | 73 (63–81) | 0.034 |
 Male sex | 1576 (59 %) | 716 (57 %) | 860 (61 %) | 0.089 |
Illness severity | ||||
 SIRS score | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.508 |
 SOFA score | 9 (6–12) | 10 (8–13) | 8 (5–11) | <0.001 |
 APACHE II score | 22 (16–28) | 23 (18–29) | 21 (16–27) | <0.001 |
 ISTH DIC score | 3 (1–4) | 4 (2–5) | 2 (1–4) | <0.001 |
 JAAM DIC score | 4 (2–6) | 5 (3–6) | 3 (2–5) | <0.001 |
Source of ICU admission | Â | Â | Â | <0.001 |
 Emergency department | 1256 (47 %) | 527 (42 %) | 729 (52 %) | - |
 Ward | 711 (27 %) | 366 (29 %) | 345 (24 %) | - |
 Other hospital | 696 (26 %) | 354 (28 %) | 342 (24 %) | - |
Pre-existing condition | ||||
 Liver insufficiency | 19 (1 %) | 12 (1 %) | 7 (1 %) | 0.171 |
 Chronic heart failure | 143 (5 %) | 76 (6 %) | 67 (5 %) | 0.122 |
 Chronic respiratory disorder | 102 (4 %) | 42 (3 %) | 60 (4 %) | 0.266 |
 Chronic haemodialysis | 209 (8 %) | 84 (7 %) | 125 (9 %) | 0.051 |
 Immunocompromised | 280 (11 %) | 130 (10 %) | 150 (11 %) | 0.899 |
New organ dysfunction (SOFA sub-scores ≥2) | ||||
 Respiratory | 1792 (88 %) | 851 (68 %) | 941 (67 %) | 0.341 |
 Cardiovascular | 1761 (66 %) | 934 (75 %) | 827 (58 %) | <0.001 |
 Renal | 1279 (48 %) | 707 (57 %) | 572 (40 %) | <0.001 |
 Hepatic | 441 (17 %) | 253 (20 %) | 188 (13 %) | <0.001 |
 Coagulation | 957 (36 %) | 591 (47 %) | 366 (26 %) | <0.001 |
Primary source of infection | Â | Â | Â | <0.001 |
 Abdomen | 881 (33 %) | 460 (37 %) | 421 (30 %) | - |
 Lung | 677 (25 %) | 269 (22 %) | 408 (29 %) | - |
 Urinary tract | 456 (17 %) | 221 (18 %) | 235 (17 %) | - |
 Bone/soft tissue | 309 (12 %) | 146 (12 %) | 163 (12 %) | - |
 Central nervous system | 57 (2 %) | 30 (2 %) | 27 (2 %) | - |
 Other/unknown | 283 (11 %) | 121 (10 %) | 162 (11 %) | - |
Other therapeutic interventions | ||||
 Immunoglobulin | 800 (30 %) | 590 (47 %) | 210 (15 %) | <0.001 |
 Low-dose steroid | 624 (23 %) | 401 (32 %) | 223 (16 %) | <0.001 |
 Renal replacement therapy | 830 (31 %) | 566 (45 %) | 264 (19 %) | <0.001 |
 PMX-DHP | 574 (22 %) | 410 (33 %) | 164 (12 %) | <0.001 |
 Surgical intervention | 1153 (43 %) | 617 (50 %) | 536 (38 %) | <0.001 |